Ruxolitinib, a non-selective JAK1/2 inhibitor approved for the treatment of myelofibrosis, reduces JAK-signal transducer activation and lowers STAT transcription signaling [67, 68]. This evidence concerns the gene SOAT1 and myelofibrosis.